

**Table 9a. Trough Concentrations of Antiretroviral Drugs for Patients Who Have Drug-Susceptible Virus (Updated January 10, 2011)**

Drug	Concentration (ng/mL)
<b>Suggested minimum target trough concentrations in patients with HIV-1 susceptible to the ARV drugs [2-9]</b>	
Fosamprenavir (FPV)	400 (measured as amprenavir concentration)
Atazanavir (ATV)	150
Indinavir (IDV)	100
Lopinavir (LPV)	1,000
Nelfinavir <sup>1</sup> (NFV)	800
Saquinavir (SQV)	100–250
Efavirenz (EFV)	1,000
Nevirapine (NVP)	3,000

<sup>1</sup>Measurable active (M8) metabolite

**Table 9b. Trough Concentrations of Antiretroviral Drugs for Treatment-Experienced Patients with Virologic Failure (Updated January 10, 2011)**

Drug	Concentration (ng/mL)
<b>Suggested minimum target trough concentrations for ART-experienced patients who have resistant HIV-1 strains</b>	
Maraviroc (MVC)	>50
Tipranavir (TPV)	20,500
<b>Median (Range) Trough Concentrations from Clinical Trials [12-14]</b>	
Darunavir (DRV) (600 mg twice daily)	3,300 (1,255–7,368)
Etravirine (ETR)	275 (81–2,980)
Raltegravir (RAL)	72 (29–118)